NICE accepts two drugs for severe plaque psoriasis

摘要

Etanercept(Enbrel)and efalizumab(Raptiva)have been recommended for the treatment of severe plaque psoriasis by the National Institute for Health and Clinical Excellence.Etanercept has been accepted for the treatment of adults with plaque psoriasis,only when the disease is severe(defined as a total psoriasis area severity index [PASI] of 10 or more and a dermatology life quality index [DLQI] of more than 10).In addition,a patient must have failed to respond to standard systemic therapies or a patient is intolerant to,or has a contraindication to,standard systemic therapies.Efalizumab is also recommended for severe plaque psoriasis,but only if a patient has failed to respond to etanercept or is intolerant to,or has a contraindication to,etanercept.